Director/PDMR Shareholding

RNS Number : 8449V

Creo Medical Group PLC

02 February 2017

 

Creo Medical Group plc

Director/PDMR Dealing

The Company announces that on 31 January 2017, Craig Gulliford, Chief Executive Officer, transferred 101,096 ordinary shares from his personal holding to his self-invested personal pension (SIPP) at a price of 93.5p per share. Furthermore, his SIPP purchased an additional 5,836 ordinary shares in the Company at a price of 93.5p per share. Following these transactions, Mr Gulliford's total interest has increased to 1,089,932 ordinary shares.

Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Craig Gulliford
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of  £0.001 each GB00BZ1BLL44
b)	Nature of the transaction	Transfer of ordinary shares to SIPP via sale and purchase
c)	Price(s) and volume(s)	Price(s) Volume(s) Sale of shares from personal holding at 93.5p per share 101,096 Purchase by SIPP at 93.5p per share 106,932
d)	Aggregated information - Aggregated volume - Price	106,932 Weighted average price of 93.5p per share
e)	Date of the transaction	31 January 2017
f)	Place of the transaction	London Stock Exchange

Contacts

Creo Medical:	Cenkos:	FTI Consulting:
Roseanne Varner	Ivonne Cantu / Camilla Hume (NOMAD)	Brett Pollard / Mo Noonan
[phone]	Michael Johnson / Russell Kerr (Sales)	[phone]
[e-mail]	[phone]	[e-mail]

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring the CROMA surgical system to market through a suite of medical instruments which the Company has designed, initially for GI therapeutic endoscopy, an area with high unmet needs. The CROMA system will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

 

END

 

 

DSHLIFFDFLIFIID